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Presentation of case
Dr. W. Spindelboeck: Due to episodic epigastric pain this 
32-year-old woman had undergone computed tomo- 
graphy (CT) 20 months previously. Contrast enhanced 
CT showed a hypodense lesion between liver segments 
IV and VIII with a diameter of 4 cm and inhomogenous 
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early enhancement suggesting hemangioma. Eight 
more lesions (diameter up to 1  cm) that were only vis-
ible in the early arterial phase were found in segments 
VI and III. Magnetic resonance imaging (MRI) 13 and 
8 months before admission showed slight progression 
(from a diameter of 4.0 to 4.6  cm) of the lesion in seg-
ment IV. At that time, the lesion appeared to be lobulated 
with a central hyperintense scar and arterial enhance-
ment, primarily compatible with “atypical” focal nodu-
lar hyperplasia (FNH). Except for occasional abdominal 
pain and a 10-year history of histamine intolerance, the 
patient was free of symptoms. She had taken thyroid 
replacement therapy (Euthyrox® 100 µg per day) for years; 
she had no previous surgery, had never received a blood 
transfusion, and was not vaccinated against hepatitis A 
or B; she neither smoked nor drank and her family his-
tory was unremarkable. The patient is a single parent of a 
healthy 10-year-old boy. Physical examination was unre-
markable; she weighed 56 kg and her height was 174 cm. 
Except for lactate dehydrogenase (LDH:296 U/l, normal 
120–240  U/l) routine laboratory tests were negative. A 
panel of antibodies to detect autoimmune and collagen 
vascular diseases was negative; thyroid stimulating hor-
mone (TSH) was 1.3 µU/ml (normal 0.1–4.0 µU/l).
During a follow-up exam in the outpatient liver clinic, 
she showed a facial flush that lasted for 2 min, although 
the situation was not psychologically upsetting. She said 
facial flushes are part of her histamine intolerance. A 
diagnostic test was performed, and she was admitted to 
the hospital for further management.
Dr. M. Fuchsjäger: Abdominal multidetector CT revealed 
a 4.0 × 3.3  cm, well circumscribed, heterogenous, 
hypodense lesion in liver segments VIII/IV with signifi-
cant contrast enhancement during the arterial and portal 
venous phases and with contrast washout during delayed 
phases (Fig. 1). Eight more lesions (diameter up to 1 cm), 
only visible in the early arterial phase, were found in 
segments VI and III. MRI studies of the liver 7 and 12 
months later both showed multiple, well-circumscribed, 
heterogenous, hypointense hepatic mass lesions with 
significant contrast enhancement (Fig.  2). Between the 
13th and 8th months before admission, the target lesion 
increased slightly in size, from 4.0 to 4.6 cm.
Taken together, the MRI studies showed hypervascular 
lesions in both lobes of the liver compatible with several 
diagnoses. The hyperintensity of the larger lesion and 
the early arterial contrast enhancement also seen in the 
smaller lesions are typical for hemangiomas. Moreover, 
upon MRI hemangiomas show a quite homogenous por-
tal venous contrast enhancement due to accumulation of 
contrast medium during the examination. So in this case, 
MRI suggests a hemangioma for several reasons. On the 
other hand, the central hyperintense scar found in one 
of the lesions could be characteristic for FNH; however, 
the MRI findings do not clearly allow a definite diagnosis.
Differential diagnosis
Dr. B. Haas: The patient under discussion is a 32-year-
old woman with nodules in the liver. Except for occa-
sional abdominal pain and histamine intolerance, she 
is asymptomatic. Twenty months earlier, CT of the liver 
showed what was first thought to be a hemangioma and 
later interpreted as an “atypical” FNH. Further MRIs 
revealed progression of the lesion (from a diameter of 4.0 
to 4.6 cm) and identified eight additional lesions (diame-
ter up to 1 cm) in the liver. Facial flushes were thought by 
the patient to be due to histamine intolerance diagnosed 
Fig. 1 Multidetector CT, axial 
images. 4.4 × 3.3 cm, well 
defined, heterogenous, and 
hypodense lesion in liver 
segments VIII and IV upon 
pre-contrast scan (a); lesion 
demonstrated significant 
enhancement in arterial (b) 
and less enhancement in 
portal venous phases (c); no 
enhancement of the irregular 
area within the lesion, and 
definite contrast washout pat-
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docrine tumor (GEP-NET). Frequently, flush symptoms 
in GEP-NETs occur in the setting of liver metastases. 
This is because most of the bioactive substances that 
are released by a GEP-NET may be metabolized by the 
liver on first pass from the splanchnic area and, more 
importantly, liver metastases provide for more tissue 
for production and release of bioactive substances into 
the circulation. Laboratory tests showed elevated serum 
LDH, with an increased ratio of LDH/AST, a possible 
marker for the presence of liver metastases. An impor-
tant diagnostic test that could suggest a GEP-NET is the 
analysis of serum chromogranin A. Chromogranin A is 
a protein found in the secretory granules of neuroendo-
crine cells, and its concentration correlates with tumor 
mass [2]. Further diagnostic steps include analysis of 
5-hydroxyindol acetic acid (5-HIAA) in a 24-h urine sam-
ple. Endoscopic investigation including capsule endos-
copy of the small bowel, abdominal sonography, and 
contrast-enhanced CT, PET, and radionuclear imaging 
such as 99mtechnetium octreotid scintigraphy and 68gal-
lium-DOTATATE (= DOTADOC) PET-CT are parts of the 
further workup.
Dr. B. Haas’s diagnosis
GEP-NET with liver metastases; clinically “carcinoid 
syndrome.”
Discussion of diagnosis
Dr. W. Spindelboeck: This patient does indeed have a gut 
neuroendocrine tumor (NET). Further history revealed 
that flush symptoms as noticed in the outpatient liver 
clinic occur 10 to 50 times per day. The patient com-
plained of bloating but denied diarrhea. The following 
10 years before. Physical examination did not show any 
abnormality and, except for LDH, routine laboratory 
tests were within normal limits.
As the patient is a native of Austria, hepatocellular carci-
noma (HCC) in a noncirrhotic liver due to chronic hepa-
titis B is unlikely. Since hepatitis serology is routinely 
tested during pregnancy in this country, an infection 
would have been revealed much earlier when the patient 
had been pregnant. It is unclear whether the patient had 
consumed foods such as wild berries or raw vegetables 
and so might have been infected with echinococcus; 
however, the MRI lesions are not typical for echinococ-
cal cysts [1]. An infection with Bartonella henselae due to 
contact with cats and a resulting bacillary peliosis hepa-
tis could be considered, but this disease predominantly 
occurs in immunosuppressed patients, is associated with 
fever, and runs a much shorter course. As to the episodic 
abdominal pain, a regular recurrence of symptoms could 
parallel the menstrual cycle, but endometriosis would 
not really explain the liver lesions. Since the panel of 
antibodies for autoimmune and collagen vascular dis-
eases was negative, an autoimmune disease can alsobe 
ruled out. The patient said she was histamine intolerant, 
but unfortunately no further information was available 
as to how this diagnosis was established 10 years ear-
lier (genetic variant? activity of diaminooxidase?). FNH 
could still be considered as a possible diagnosis, but it 
would not have required prompt admission to the hospi-
tal. The assumed diagnosis of a liver hemangioma based 
on the CT scan, which showed a hypodense lesion with 
inhomogenous early arterial contrast enhancement, 
appears unlikely since the lesion had progressed in size.
For my differential diagnosis, I have to address the 
facial flush presumed to be due to histamine intolerance. 
Flush symptoms can be caused by enhanced release of 
vasoactive substances such as serotonin and bradyki-
nin, mostly due to a gastroenteropancreatic neuroen-
Fig. 2 MRI: T2W image dem-
onstrates a large, well-circum-
scribed hyperintense mass 
(a). Post-contrast T1W images 
showed highly heterogenous 
arterial enhancement, the 
central hyperintense area 
probably represents necrosis 
(b). In portal venous (c) and 
delayed phases (d), the lesion 
is iso- to hypointense to liver 
parenchyma with the central 
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This patient underwent SSRS (Fig. 3) and 18fluro-DOPA 
PET/CT (Fig.  4) to confirm the final diagnosis and her 
regular follow-up includes these studies.
Dr. M. Fuchsjäger: Radiologic imaging currently lacks 
specificity for GEP-NETs, which are often mistaken for 
more common lesions. Due to their highly variable 
appearance, NET liver metastases may first be taken for 
benign lesions such as adenoma or hemangioma or con-
fused with another hepatic malignancy such as HCC or 
cholangiocarcinoma. Since these imaging findings may 
overlap with other liver neoplasms, diagnosis of liver 
metastases from NETs still rests primarily on pathologi-
cal analysis and immunochemistry of biopsy and/or sur-
gical specimens [13].
Liver metastases seen on CT images most frequently 
are less attenuated than surrounding liver parenchyma 
on pre-contrast images but strongly enhance post-con-
trast, mimicking hemangioma. Metastases of NETs may 
be difficult to identify and delineate on CT as they may 
be isodense with the liver on portal venous phase imag-
ing. In some cases a lesion may be seen only on one of 
laboratory results were obtained: serum chromogranin 
A 1061  ng/ml (normal 0–99  ng/ml), serum serotonin 
2063 ng/ml (normal 80–450 ng/ml), and urinary 5-HIAA 
118 mg/24h (normal 6–10 mg/24h). For further staging, 
MRI of the small intestine and the liver was performed.
Dr. G. J. Krejs: Just a short remark—the patient was 
admitted immediately so that somatostatin analog ther-
apy could begin without delay.
Some epidemiological facts: Although previously 
regarded as rare, GEP-NETs represent the second most 
common digestive malignancy after adenocarcinomas 
[3, 4]. Based on data of the Surveillance, Epidemiology 
and End Results (SEER) program of the National Can-
cer Institute including 29,664 patients, the incidence 
is estimated to be 3.65/100,000 persons per year [5]. In 
Austria, Dr. Niederle found a similar incidence [6]. The 
incidence of GEP-NET has increased in recent decades; 
the expanding use of sophisticated imaging studies is 
believed to play a role in this development, but there 
seems to be a true increase. GEP-NETs mostly occur in 
the small intestine (31 %), followed by rectum (26 %), 
colon (18 %), pancreas (12 %), and appendix (6 %) [7]. The 
presence of liver metastases depends on the site of the 
primary tumor, tumor extent (T-stage), histological dif-
ferentiation, and proliferative activity (grading; G1-G3). 
Pancreas, right hemicolon, and small intestine are the 
most frequent primary tumor sites presenting with dis-
tant metastases upon initial diagnosis. Some data show 
that 80–90 % of patients with small intestinal neuroendo-
crine neoplasia also have liver metastases [8]. In patients 
with “carcinoid syndrome,” distant metastases are regu-
larly observed, and they are found more frequently in 
patients with poorly differentiated endocrine carci-
noma (NEC G3) than in those with well-differentiated 
NET G1-G2 [8]. Metastases in NET patients can only be 
assessed with sensitive imaging techniques. In addition 
to MRI, radionuclear imaging was also performed in the 
discussed patient, and Dr. Lipp will show the results.
Dr. R. Lipp: NET cells express somatostatin receptors 
(SSR) which are the target for radionuclear tracers dur-
ing somatostatin-receptor scintigraphy (SSRS). For SSRS, 
a gamma emitter (single-photon emission CT, SPECT) 
such as 111In-DTPA-octreotide (OctreoScan™) and 99mTc-
tektrotyde®, or a positron emitter (positron emission 
tomography, PET) such as 68Ga-octreotide, 68Ga-DOTA-
TOC, and 64Cu-DOTA-TATE is used.
18Fluro-DOPA PET/CT is another radionuclear 
method to assess the metabolic activity of GEP-NET cells 
independent of the SSR status. In NET cells the activity 
of DOPA-decarboxylase that decarboxylates the amin-
precursor DOPA to a biogenic amin is increased [9–11]. 
Depending on the degree of differentiation, GEP-NET 
cells take up and metabolize 18fluro-DOPA differently. In 
one third of GEP-NET patients this investigation provides 
pivotal and therapeutically important information that 
cannot be obtained by other morphologic and functional 
imaging methods [12].
Fig. 3 Somatostatin receptor imaging with 111In-pentetreotide 
(OctreoScan™) showing somatostatin receptor expression 
of the liver metastasis in liver segment IV and additionally in 
mesenteric lymph nodes (red arrows). Normal enhancement is 
seen in spleen (S), kidneys (K), and urinary bladder (U)
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Dr. P. Kornprat: Surgical resection of liver metastases is 
known to have a positive effect on overall survival and 
quality of life due to alleviation of symptoms related to 
secretion of serotonin or other mediators in functioning 
tumors [8]. Sarmiento et al. reported that 95 % of patients 
with specific symptoms at the time of surgery experi-
enced improvement afterwards. According to the Euro-
pean Neuroendocrine Tumor Society (ENETS) Guide-
lines surgical resection with curative intent remains 
the gold standard in the treatment of liver metastases, 
achieving a survival rate of 60–80 % at 5 years. Prereq-
uisites are (1) a tumor classification of NET G1/G2, i.e. 
well-differentiated, resectable lesions with acceptable 
morbidity and < 5 % mortality; (2) absence of right ven-
tricular failure; (3) absence of unresectable lymph nodes 
and extra-abdominal metastases; and (4) absence of dif-
fuse or unresectable peritoneal carcinomatosis [8].
When NETs are associated with endocrine syndromes, 
debulking surgery is attempted whenever feasible. Deb-
ulking procedures include not only resection of the pri-
mary tumor, liver metastases, and lymph nodes but also 
ablative therapies that remove > 90 % of the tumor [8, 
18–20]. In patients with “carcinoid syndrome,” periopera-
tive treatment with SSA is indicated to prevent intra- and 
postoperative carcinoid crisis [21, 22].
A two-step surgical approach was chosen for this 
patient: First, a 75-cm-long segment of the lower small 
bowel with adjacent mesenteric nodes was resected. 
There were no intra- or postoperative complications.
Depending on the number and localization of the 
metastases, up to 65–70 % of the whole liver volume (in 
patients with normal liver parenchyma) can be removed 
surgically [23, 24], and large parts of our patient’s liver 
had to be resected. Since the future parenchymal rem-
nant would have been too small, the right portal vein 
branches had to be embolized to induce hypertrophy of 
the left lobe of the liver. This was done 17 days after the 
first operation and 10 weeks before an extended hemi-
hepatectomy of the right lobe with an atypical resection 
of segment III and lobus quadratus (Fig. 5) could be car-
ried out. The second operation was also performed with-
out complications.
Dr. C. Lackner: Macroscopically, the resected segment 
of ileum was 75 cm long and contained three tumors of 2, 
1.5, and 3 cm in diameter. The tumors were 1.5 and 6 cm 
apart  and were located 20 cm from both, the oral and 
aboral margin of resection. All three tumors extended 
beyond the mucosa into the small bowel wall. The serosa 
was intact. The mesentery showed another mass of 
5.0 × 3.5 × 3.0  cm that extended to the resection margin 
and five lymph nodes with diameters of up to 2 cm.
Microscopically, all three tumors found in the resected 
ileum and the tumor in the mesentery could be identified 
morphologically and immunohistochemically as NETs 
(Fig. 6). They were well demarcated and extended to the 
subserosa.
the three phases (pre-contrast, arterial phase, and portal 
venous phase) [14, 15].
MRI has a higher sensitivity for identifying the pri-
mary tumor. Tumors usually have low signal intensity on 
T1-weighted sequences (75 %) and high signal intensity 
on T2-weighted sequences (94 %), being hypervascular 
on arterial post-gadolinium images: 15 % of liver metas-
tases were only seen on the immediate post-gadolinium 
images. The tumors are most conspicuous on fat-sup-
pressed T1-weighted images [15, 16]. Both CT and MRI 
can be used to stage nodal and distant metastatic disease 
as part of preoperative planning [17].
Dr. G. J. Krejs: After the GEP-NET had been diagnosed the 
patient was immediately treated with somatostatin ana-
log (SSA) and 3 months later underwent tumor debulk-
ing, i.e. resection of the primary tumor and liver metas-
tases. Dr. Kornprat was the surgeon and will explain and 
comment on the treatment.
Fig. 4 18Fluro-DOPA PET showing increased DOPA metabo-
lism in neuroendocrine metastases in the liver and mesenteric 
lymph nodes (red arrows). Note additional metastatic sites in 
the right lobe of the liver and pelvis not shown in somatostatin 
receptor imaging (blue arrows). Normal enhancement due to 
biliary and urinary excretion of the marker is seen in the upper 
small bowel (SB) and urinary bladder (U)
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polymorphic and hyperchromatic nuclei and sparse 
cytoplasm. They produce fewer neurosecretory gran-
ules and neuroendocrine markers. “Grade” refers to the 
inherent biologic aggressiveness of the tumor. Low-grade 
NETs are relatively indolent; intermediate-grade tumors 
show less predictable, moderately aggressive behavior; 
and high-grade tumors (i.e., NECs) are extremely aggres-
sive [25].
The proliferative rate of a NET provides significant 
prognostic information and can be assessed as the num-
ber of mitoses per unit area of tumor (usually expressed 
as mitoses per 10 HPF) or as the percentage of neoplastic 
cells immunolabeling for the proliferation marker Ki67 
[26, 27].
In this patient, fewer than two mitoses/10 HPF and a 
Ki67 index ≤ 2 % were found, corresponding to NET grade 
1 (NET G1). The tumor in the mesentery extended to less 
than 1 mm from the resection margin, so that there was 
some uncertainty as to whether the tumor had been com-
pletely resected. There were neural sheath and venous 
invasions at multiple sites in the area of the mesenteric 
root. Moreover, a metastasis was found in one of the five 
lymph nodes in the resected mesentery. The tumor cells 
were immunohistochemically positive, with antibodies 
against chromogranin and synaptophysin. Some of the 
tumor cells reacted with antibodies against serotonin 
but not with those against gastrin, adrenocorticotropin, 
somatostatin, and pancreatic polypeptide.
The liver specimen measured 17.0 × 10.5 × 5.0  cm. A 
tumor of 5.5 × 4.0 × 4.0  cm extending to the resection 
margin was found on the cut surface, which on histol-
ogy proved to represent a liver metastasis of the NET 
described above.
According to the UICC 2009 [28] the tumor could be 
classified as G1 pT3(m) N1 M1 (HEP) V1 Pn1, R2.
The prognosis for jejunoileal NETs depends on tumor 
size and the extent of tumor infiltration, the grade of dif-
ferentiation, and the presence of metastases. With liver 
metastases, the 5- and 10-year survival rates amount to 
35 and 15 %; without liver metastases the rates increase 
to 72 and 60 %, respectively [29].
Dr. G. J. Krejs: The term NET was based on the hypoth-
esis that the cells of neuroendocrine neoplasms originate 
from the embryonic neural crest. Based on findings that 
most of these neoplastic cells resemble cells of endoder-
mal origin, this concept was discarded years ago [25]. 
However, neoplastic cells possess features of both neural 
and epithelial cells, and for this reason, the most recent 
WHO classification of tumors of the digestive system has 
once again recommended the use of the term “neuro-
endocrine” [29]. NETs are diverse in their site of origin 
and clinical behavior, ranging from highly aggressive 
cancers to low-grade tumors of the small bowel. Symp-
toms arise from both the tumor burden and the secre-
tion of bioactive hormones by “functioning tumors” as 
observed in this patient. While high-grade tumors (G3) 
are often treated with chemotherapy, somatostatin ana-
logs to alleviate the consequences of hormone secretion 
Systems of nomenclature reflect differentiation and 
grading features of NETs (Table  1). Generally, NETs are 
divided into well-differentiated and poorly differentiated 
tumors (the latter referred to as neuroendocrine carci-
nomas: NEC). Differentiation and grade of the tumor are 
linked; there are, however, subtle differences between 
the two concepts. “Differentiation” refers to the extent to 
which the neoplastic cells resemble their non-neoplastic 
counterparts. Well-differentiated NETs have characteris-
tic organoid arrangements of tumor cells, with nesting, 
trabecular or gyriform patterns; the cells are relatively 
uniform with monomorphic nuclei. They produce abun-
dant neurosecretory granules, reflected by the strong 
immunoexpression of neuroendocrine markers such 
as chromogranin A. NECs less closely resemble non-
neoplastic neuroendocrine cells, and their architecture 
is less well organized. The tumor cells contain enlarged 
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Fig. 5 Intraoperative image after completion of the extended 
hemihepatectomy. (a) right diaphragm, (b) margin of resection 
at the remaining left lobe of the liver, (c) inferior vena cava, 
(d) common bile duct
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After resection of the primary tumor, subsequent 
extended hemihepatectomy and continued lanreotide 
treatment, chromogranin A levels further decreased to 
71 ng/ml. Due to vertigo and hypotension as side effects, 
the dosage of lanreotide had to be reduced from 120 mg/
month to 90  mg/month. One year after surgery, stag-
ing revealed micrometastases in the remaining liver on 
PET scan, but they were not detectable by MRI; the dis-
ease state so was classified as “stable.” The patient has 
no more flushes, and urinary 5-HIAA is not elevated. 
According to the CLARINET (A Randomized Double-
Blind Placebo-Controlled Study of Lanreotide Antiprolif-
erative Response in Patients with Gastroenteropancreatic 
Neuroendocrine Tumors) study, lanreotide (Somatuline 
Autogel®) significantly prolongs the progression-free sur-
vival (PFS) of patients with GEP-NETs (p = 0.0002; hazard 
ratio 0.47; 95 % CI: 0.30–0.73). The antiproliferative effect 
of lanreotide is statistically significant for patients with 
midgut NET and clinically relevant for those with pancre-
atic NET. As treatment with lanreotide also prolongs the 
PFS of GEP-NET patients with high-grade tumors (G2, 
Ki67 3–10 %) and higher hepatic tumor burden (> 25 %) 
[40], treatment with SSA is currently the best therapeu-
tic option for our patient to prolong PFS. At the time of 
submission of this manuscript she had already been fol-
lowed for 4 years and is doing well.
Dr. G. J. Krejs: Which further or future therapeutic options 
could be considered for this patient? Could liver trans-
plantation be an option?
Dr. P. Kump: According to the ENETS Guidelines [8], SSA 
therapy and tumor debulking comprise the first thera-
peutic approach for patients with a functioning NET. 
of “functioning tumors” are the appropriate therapy for 
low-grade NETs [30, 31]. Recent studies on treatment of 
pancreatic NETs with sunitinib [32] and everolimus [33] 
provide evidence for the importance of angiogenesis and 
the mTOR pathway in the growth of NETs, but there is still 
a significant unmet need to improve outcomes in this dis-
ease. Due to the diagnosis of a low-grade GEP-NET, our 
patient was treated with somatostatin analog before sur-
gery. Dr. Kump is her attending physician and will report 
on the therapeutic progress and follow-up of the patient 
under somatostatin analog therapy.
Dr. P. Kump: G protein-coupled receptors (GPRs) in 
NETs have been studied extensively. Since stimulation or 
inhibition of such receptors can influence tumor growth, 
a number of GRPs have been found to be excellent targets 
for GEP-NET diagnosis and treatment [34]. Somatostatin 
receptors (SSRs) belong to the GPR family, are expressed 
on the cell membranes of various tumors including GEP-
NET, and bind somatostatin and its therapeutic analogs 
(octreotide and lanreotide) [35]. Targeting SSRs with 
somatostatin analogs (SSAs) can block the secretion of 
biologically active substances from the tumor cells [36–
38] and may inhibit cell growth and induce apoptosis 
[39]. Some tumors, however, are resistant to SSAs and it 
is not known whether the defect lies in the activation of 
the SSR or downstream signaling events [31]. After our 
patient received a SSA (lanreotide 120  mg/month) pre-
operatively, there was a major decrease in chromogranin 
A levels from 1068 to 180 ng/ml (upper limit of normal 
99  ng/ml) with a reduction in the frequency of flushes 
from > 20 per day to 2–3 per day. To prevent a carcinoid 
crisis, SSA therapy should always be started preopera-
tively and should be continued throughout the surgery.
Fig. 6 NET of the ileum with 
metastasis to the mesentery. 
(a) NET (arrow) extending to 
the muscularis propria (in-
dicated by star) of the ileum 
(H&E; 20x); (b) metastasis 
to the mesentery (indicated 
by star), surrounded by 
fibrous pseudocapsule (H&E; 
20x); (c) tumor cells with 
mild cytological atypia and 
enlarged nuclei with salt-and-
pepper chromatin (H&E; 400x); 
(d) very few tumor cell nuclei 
stain with antibodies against 
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Final diagnosis
Three neuroendocrine tumors of the ileum (G1, “carci-
noids”) with metastases to the mesenteric lymph nodes 
and the liver.
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